Market
Story
Neuralink to Expand Human Trials to UK, Canada, UAE, and New Zealand in 2025
Jan 9, 2025, 06:50 AM
Elon Musk's Neuralink has announced plans to expand its human trials to several countries, including the UK, Canada, New Zealand, and the UAE, in 2025. Neuralink, which develops brain-computer interface (BCI) technology, has already implanted devices in three patients. The company aims to address conditions such as paralysis, ALS, and blindness, with Musk stating that the technology could potentially enable paralyzed individuals to walk again by bypassing spinal cord damage. Human trials are currently underway in the US, UK, and Canada, with applications open for participants.
View original story
Similar markets
Enhanced mobility for ALS patients • 25%
Improved communication for paralyzed patients • 25%
New treatment for epilepsy • 25%
Other significant milestone • 25%
Extended battery life • 25%
Other major update • 25%
Increased electrode count • 25%
New software features • 25%
Case study on paralysis treatment • 25%
Case study on ALS treatment • 25%
No high-profile case study • 25%
Case study on other neurological conditions • 25%
More than 30 • 25%
Fewer than 20 • 25%
26 to 30 • 25%
20 to 25 • 25%
Depression • 25%
Parkinson's disease • 25%
Epilepsy • 25%
Other condition • 25%
